List of Otovel drug patents

Otovel is owned by Laboratorios Salvat.

Otovel contains Ciprofloxacin Hydrochloride; Fluocinolone Acetonide.

Otovel has a total of 1 drug patent out of which 0 drug patents have expired.

Otovel was authorised for market use on 29 April, 2016.

Otovel is available in solution/drops;otic dosage forms.

Otovel can be used as treatment of acute otitis media.

The generics of Otovel are possible to be released after 24 March, 2030.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8932610 LABORATORIOS SALVAT Aqueous clear solutions of fluocinolone acetonide for treatment of otic inflammation
Mar, 2030

(7 years from now)

Drugs and Companies using CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE ingredient

Market Authorisation Date: 29 April, 2016

Treatment: Treatment of acute otitis media

Dosage: SOLUTION/DROPS;OTIC

More Information on Dosage

OTOVEL family patents

2

European Union

1

Korea, Republic of

1

Hong Kong

1

Poland

1

United States

1

Australia

1

Russia

1

Canada

1

Denmark

1

Argentina

1

Mexico

1

Spain

1

Japan

1

China

1

Brazil

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in